Prednisone Is More Effective Than Prednisolone Metasulfobenzoate in the Treatment of Bullous Pemphigoid

Lebrun‐Vignes, Bénédicte; Roujeau, Jean‐Claude; Bernard, Philippe; Delaporte, E.; Joly, P.; Prost, Cathérine; Vaillant, L.; Herson, S.; Chosidow, Olivier

doi:10.1001/archderm.135.1.89

Search citation statements

Order By: Relevance

Paper Sections

Select...

Comment1

Effectiveness and Side Effects Of Systemic Corticosteroids I1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2003

2023

Publication Types

Select...

Article5

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 12 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it has been previously demonstrated that some available prednisolone salts are not bioequivalent, and their efficacy might be less than prednisone, making comparison between studies difficult. 11,12 …”

Section: Commentmentioning

confidence: 99%

Randomized Controlled Trials Needed for Bullous Pemphigoid Interventions

ía-Romero¹

2012

Arch Dermatol

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 99%

Randomized Controlled Trials Needed for Bullous Pemphigoid Interventions

ía-Romero¹

2012

Arch Dermatol

View full text Add to dashboard Cite

“…When pooled, the results of a few controlled trials comparing oral corticosteroids alone to oral corticosteroids in association with an adjuvant therapy suggested that the rate of disease control was 0% with 0.3 mg/kg (18), 60–80% with 1 mg/kg (18–21), and 90% with 1.5 mg/kg of prednisolone (18). Based on the above results and on the demonstration that the prednisolone brand available in France had a poorer biodisponibility than prednisone (22), most French teams agreed on routinely treating BP patients with oral prednisone at an initial dosage of 1 mg/kg/day. This initial dose was maintained for two weeks after the control of the disease, and the prednisone dose was then tapered by 15% every two weeks for a total duration of treatment of about one year.…”

Section: Effectiveness and Side Effects Of Systemic Corticosteroids Imentioning

confidence: 99%

Treatment of Bullous Pemphigoid

Fontaine¹,

Joly

Roujeau³

2003

The Journal of Dermatology

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is the most frequent auto-immune blistering skin disease. Up to recently, it was treated with oral corticosteroids. High dose steroids are poorly tolerated in the elderly and probably contributed to the high mortality rates observed in several cohorts. For years, efforts have been devoted to looking for steroid sparing agents including immunosuppressive drugs, plasma exchanges, intravenous immunoglobulins, tetracycline. Many seemed useful in open series but proved ineffective or marginally effective when tested in randomized controlled trials. An important breakthrough was the demonstration by a large randomized trial that a "super-potent" topical corticosteroid (clobetasol propionate) was not only associated with a significant decrease in severe complications and mortality of BP patients but was also more effective than oral prednisone. New strategies for BP should include topical clobetasol propionate as the first line treatment and consider adjuvant therapy only in the very rare cases that are either resistant to or intolerant of this treatment.

show abstract